National guidelines for high-cost drugs in Brazil
- Paulo Picon
- 3 de abr. de 2013
- 1 min de leitura
Atualizado: 27 de jan. de 2023
National guidelines for high-cost drugs in Brazil: achievements and constraints of an innovative national evidence-based public health policy
Alberto Beltrame and
Published online by Cambridge University Press
ABSTRACT
Introduction: The translation of best evidence into practice has become an important purpose of policy making in health care. In Brazil, a country of continental dimensions with widespread regional and social inequalities, the dissemination and use of the best-evidence in policy making is a critical issue for the healthcare system.
Objectives: The main purpose of this study is to describe an evidence-based public health policy with special emphasis on guidelines creation for high-cost medicines. We also describe how that strategy was diffused to the judiciary system and to other parts of the healthcare system.
Results: We present an 11-year follow-up of a national project for creating and updating guidelines for high-cost medicines in Brazil. A total of 109 national guidelines were published (new or updated versions) for 66 selected diseases, the first such effort in Brazilian history. The project influenced the Brazilian legislature, which has recently established a Federal Law requiring national guidelines for any new technology listed for payment by the Brazilian public healthcare system.
Conclusion: We were able to involve many different stakeholders in a partnership between academia and policy makers, which made possible the widespread dissemination of the clinical practice guidelines. Problems and constraints were also encountered. This evolving public health strategy might be useful for other developing countries.
Issue 2 , April 2013 , pp. 198 - 206
Comentários